Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is set to announce its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The company had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. During the same quarter in the prior year, the company earned ($1.51) earnings per share. The business’s revenue was up 28.4% compared to the same quarter last year. On average, analysts expect Agios Pharmaceuticals to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Trading Up 1.6 %

NASDAQ:AGIO opened at $46.83 on Wednesday. The firm has a 50 day moving average of $44.69 and a 200-day moving average of $41.98. Agios Pharmaceuticals has a 1 year low of $20.04 and a 1 year high of $53.28. The stock has a market capitalization of $2.66 billion, a P/E ratio of -7.41 and a beta of 0.75.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $60.00 to $56.00 in a research note on Friday, September 27th. Raymond James reissued an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $52.00.

Insider Activity

In other news, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the transaction, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.